{"id":"W2070028004","doi":"10.1016/j.jval.2014.03.485","title":"Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Trametinib; Dacarbazine; Vemurafenib; Medicine; Internal medicine; Oncology; Melanoma; Metastatic melanoma; Chemotherapy; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005976671,0.0002011984,0.0004122927,0.00008249712,0.0001060073,0.000007478056,0.0001066567,0.00009422216,0.000009730421],"category_scores_gemma":[0.0003466972,0.0001677451,0.0001377713,0.0001158724,0.00006044181,0.000004366301,0.00001595613,0.00006078719,0.000003252834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004180243,"about_ca_system_score_gemma":0.001139958,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1043076,"about_ca_topic_score_gemma":0.05927528,"domain_scores_codex":[0.9984176,0.0003682311,0.0002917186,0.0004169065,0.00008919149,0.0004163854],"domain_scores_gemma":[0.99896,0.0003140467,0.0001370128,0.0002338303,0.000117807,0.0002373173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04201585,0.01013364,0.01306191,0.01030586,0.004300252,0.0002551324,0.03240694,0.07226029,0.2926868,0.1203938,0.0008062577,0.4013733],"study_design_scores_gemma":[0.04832196,0.1431516,0.03018874,0.001660128,0.0003384264,0.0003022903,0.006877932,0.010196,0.7002456,0.01042271,0.04608666,0.002207901],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993044,0.0006448592,0.002322613,0.0004550146,0.0001624546,0.00231288,0.0005046987,0.000007789658,0.0005457147],"genre_scores_gemma":[0.9965643,0.0001604766,0.002348259,0.0001763646,0.00007155928,0.0003240692,0.0002226133,0.000028755,0.0001036543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4075588,"threshold_uncertainty_score":0.9578905,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0471651896086674,"score_gpt":0.3426153436142328,"score_spread":0.2954501540055655,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}